CAR inhibitors to treat myocardial infarction (CARTI)

The Coxsackievirus- and Adenovirus-Receptor (CAR) is a cell contact protein that also mediates virus entry. It is essential for early cardiac development. CAR-deficient mice are protected from Coxsackievirus infection at the expense of only minor health related issues. Here, we will use a translational approach, to evaluate CAR as a therapeutic target and to develop CAR inhibitors to treat cardiac disease. Building on our preliminary evaluation of different CAR inhibitors, we will focus on the development and validation of a human Anti CAR antibody. With this tool, we aim to improve cardiomyocyte survival after actute myocardial infarction, remodeling, and contractile function. This includes primarily work in tissue culture, which will subsequently be validated in suitable animal models. We are convinced that CAR is an excellent therapeutic target for myocardial infarction based on (1) the protective effect of CAR deficiency on myocardial infarction, (2) Access to inhibitors, and (3) the minor extend of undesired side effects of CAR-deficiency.